FCF Margin % is calculated as Free Cash Flow divided by its Revenue. EirGenix's Free Cash Flow for the
three
months ended in Dec. 2025 was NT$340 Mil. EirGenix's Revenue for the
three
months ended in Dec. 2025 was NT$364 Mil. Therefore, EirGenix's FCF Margin % for the quarter that ended in Dec. 2025 was 93.38%.
The historical rank and industry rank for EirGenix's FCF Margin % or its related term are showing as below:
TPE:6589'
s FCF Margin % Range Over the Past 10 Years
Min: -514.32 Med: -127.26 Max: -11.76
Current: -131.7
During the past 13 years, the highest FCF Margin % of EirGenix was -11.76%. The lowest was -514.32%. And the median was -127.26%.
TPE:6589's FCF Margin % is ranked worse than 56.78% of 951
companies
in the Biotechnology industry
Industry Median: -82.65
vs TPE:6589: -131.70
EirGenix FCF Margin % Related Terms
EirGenix FCF Margin % Historical Data
* Premium members only.
The historical data trend for EirGenix's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6589 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, EirGenix's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EirGenix FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, EirGenix's FCF Margin % distribution charts can be found below:
* The bar in red indicates where EirGenix's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EirGenix (TPE:6589) has a FCF Margin % of 93.38% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on EirGenix and its competitors. According to the industry distribution chart, EirGenix ranks #540 out of 951 companies in the Biotechnology industry, placing it in the top 56.8%.
Is EirGenix's FCF Margin % too high?
EirGenix's current FCF Margin % is 93.38%. Based on the distribution chart, EirGenix ranks #540 out of 951 companies in the Biotechnology industry, which is below the industry midpoint. Overall, EirGenix has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does EirGenix's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, EirGenix ranks #540 out of 951 companies for FCF Margin %. This places EirGenix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on EirGenix and its competitors. EirGenix's current FCF Margin % is 93.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EirGenix stock overvalued right now?
Based on GuruFocus' analysis, EirGenix (TPE:6589) is currently considered Possible Value Trap. The stock's GF Value™ is NT$92.26, compared to a current price of NT$49.70 — trading 46.1% below its estimated fair value. The current FCF Margin % is 93.38%. EirGenix's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For EirGenix (TPE:6589), the current FCF Margin % is 93.38% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is EirGenix (TPE:6589) Overvalued in 2026?
Based on GuruFocus' analysis, EirGenix stock appears to be undervalued.
The current stock price of NT$49.70 is trading 46.1% below its estimated GF Value™ of NT$92.26.
GuruFocus considers EirGenix to be Possible Value Trap.
Key valuation signals for TPE:6589:
FCF Margin %: 93.38%
GF Value™: NT$92.26 vs. price of NT$49.70 (46.1% below fair value)
No single metric tells the full story. See the TPE:6589 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
EirGenix Inc is engaged in the research and development of biosimilars and new drugs, as well as biopharmaceutical contract development and manufacturing services, which included cell line construction platforms, process development platforms, analytical science and protein identification. Its products include CRM197 CARRIER PROTEIN, PRODUCT PIPELINE, COVID-19 ANTIGEN RAPID TEST. The revenue is derived from biopharmaceutical contract development and manufacturing services, sales of authorization and cooperative development, and sales of goods. Geographically, it operates in Japan, Taiwan, USA and Canada, Mainland China, Hong Kong, and Macao, and Europe, Others.
58GF Score
Get the complete analysis for TPE:6589
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6589 has been successfully added to your 
